Overcoming radiation resistance in inflammatory breast cancer

Cancer

Volumn 116, Issue SUPPL. 11, 2010, Pages 2840-2845

  Woodward, Wendy A ^a   Debeb, Bisrat G ^a   Xu, Wei ^a   Buchholz, Thomas A ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Cell lines; Chemotherapy; History; Inflammatory breast cancer; Mammospheres; Radiation; Stem cells; Surgery

Indexed keywords

BREAST CANCER; CANCER GROWTH; CANCER STEM CELL; CANCER SURVIVAL; CONFERENCE PAPER; HUMAN; HUMAN CELL; INFLAMMATORY BREAST CANCER; MASTECTOMY; POSTOPERATIVE CARE; PRIORITY JOURNAL; RADIOSENSITIVITY; RADIOSENSITIZATION; RISK BENEFIT ANALYSIS; TUMOR VOLUME; ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CELL SURVIVAL; CHEMORADIOTHERAPY; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; FLOW CYTOMETRY; HIGH RISK PATIENT; MAJOR CLINICAL STUDY; PRIMARY TUMOR; PROTEIN EXPRESSION; RADIATION DOSE FRACTIONATION; RETROSPECTIVE STUDY; RISK ASSESSMENT; TREATMENT DURATION; TREATMENT PLANNING;

BREAST NEOPLASMS; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; INFLAMMATION; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY DOSAGE;

CAPECITABINE; CD24 ANTIGEN; FLUOROURACIL; HERMES ANTIGEN; RADIOSENSITIZING AGENT;

EID: 77952725632     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25173     Document Type: Conference Paper

References (22)

1. Singletary SE, Allred C, Ashley P, et al. Staging system for breast cancer: revisions for the 6th edition of the AJCC Cancer Staging Manual. Surg Clin North Am. 2003;83:803-819.
2. Wingo PA, Jamison PM, Young JL, Gargiullo P. Population-based statistics for women diagnosed with inflammatory breast cancer (United States). Cancer Causes Control. 2004;15:321-328. (Pubitemid 38988041)
3. Barker JL, Montague ED, Peters LJ. Clinical experience with irradiation of inflammatory carcinoma of the breast with and without elective chemotherapy. Cancer. 1980;45:625-629.
4. Fleming RY, Asmar L, Buzdar AU, et al. Effectiveness of mastectomy by response to induction chemotherapy for control in inflammatory breast carcinoma. Ann Surg Oncol. 1997;4:452-461. (Pubitemid 127725217)
5. Panades M, Olivotto IA, Speers CH, et al. Evolving treatment strategies for inflammatory breast cancer: a population-based survival analysis. J Clin Oncol. 2005;23:1941-1950. (Pubitemid 46211373)
6. Perez CA, Fields JN, Fracasso PM, et al. Management of locally advanced carcinoma of the breast. II. Inflammatory carcinoma. Cancer. 1994;74(1 suppl):466-476.
7. Thoms WW Jr, McNeese MD, Fletcher GH, Buzdar AU, Singletary SE, Oswald MJ. Multimodal treatment for inflammatory breast cancer. Int J Radiat Oncol Biol Phys. 1989;17:739-745. (Pubitemid 19250526)
8. Bristol IJ, Woodward WA, Strom EA, et al. Locoregional treatment outcomes after multimodality management of inflammatory breast cancer. Int J Radiat Oncol Biol Phys. 2008;72:474-484.
9. Kyndi M, Sorensen FB, Knudsen H, Overgaard M, Nielsen HM, Overgaard J. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group. J Clin Oncol. 2008;26:1419-1426.
10. Woodward WA, Buchholz TA. The role of locoregional therapy in inflammatory breast cancer. Semin Oncol. 2008;35:78-86. (Pubitemid 351282389)
11. Phillips TM, McBride WH, Pajonk F. The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst. 2006;98:1777-1785. (Pubitemid 46017929)
12. Woodward WA, Chen MS, Behbod F, Alfaro MP, Buchholz TA, Rosen JM. WNT/beta-catenin mediates radiation resistance of mouse mammary progenitor cells. Proc Natl Acad Sci U S A. 2007;104:618-623. (Pubitemid 46123074)
13. Xiao Y, Ye Y, Yearsley K, Jones S, Barsky SH. The lymphovascular embolus of inflammatory breast cancer expresses a stem cell-like phenotype. Am J Pathol. 2008;173:561-574.
14. Greenbaum MP, Strom EA, Allen PK, et al. Low locoregional recurrence rates in patients treated after 2000 with doxorubicin based chemotherapy, modified radical mastectomy, and post-mastectomy radiation. Radiother Oncol. In press.
15. Dontu G, Abdallah WM, Foley JM, et al. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev. 2003;17:1253-1270.
16. Woodward WA, Bristow RG. Radiosensitivity of cancer-initiating cells and normal stem cells (or what the Heisenberg uncertainly principle has to do with biology). Semin Radiat Oncol. 2009;19:87-95.
17. Zhang M, Behbod F, Atkinson RL, et al. Identification of tumor-initiating cells in a p53-null mouse model of breast cancer. Cancer Res. 2008;68:4674-4682.
18. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003;100:3983-3988. (Pubitemid 36418143)
19. Gaui MF, Amorim G, Arcuri RA, et al. A phase II study of second-line neoadjuvant chemotherapy with capecitabine and radiation therapy for anthracycline-resistant locally advanced breast cancer. Am J Clin Oncol. 2007;30:78-81. (Pubitemid 46213829)
20. Dunst J, Debus J, Rudat V, et al. Neoadjuvant capecitabine combined with standard radiotherapy in patients with locally advanced rectal cancer: mature results of a phase II trial. Strahlenther Onkol. 2008;184:450-456.
21. Krishnan S, Janjan NA, Skibber JM, et al. Phase II study of capecitabine (Xeloda) and concomitant boost radiotherapy in patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2006;66:762-771.
22. Perkins GH, Middleton LP, Tran R, et al. Concurrent chemoradiation with capecitabine achieves meritable response and local control for inoperable and recurrent neoadjuvant chemotherapy refractory breast cancer. Paper presented at: San Antonio Breast Cancer Symposium; December 13-16, 2007; San Antonio, Tex. Paper 4074.